Helsinn Group, Switzerland announces a license agreement for netupitant - palonosetron fixed dose combination with CJ CheilJedang, South Korea for Korea
Lugano (ots)
Helsinn Group announces that on September 18th it has signed a license agreement with CJ CheilJedang, Korea for Helsinn's new product for potential use in the prevention of chemotherapy-induced nausea and vomiting (CINV). The agreement covers the exclusive license and distribution rights for a combination antiemetic agent (in both oral and intravenous forms) containing netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron, a serotonin-3 (5-HT3) receptor antagonist in Korea. With the agreement, CJ CheilJedang and Helsinn have expanded their business partnership in cancer supportive care. In fact, palonosetron had already previously been licensed from Helsinn for the Korean market. The fixed dose combination of netupitant and palonosetron is an innovative drug combining two different compounds in one fixed dose capsule enhancing patient compliance. It is currently in Phase III clinical development in the US for the prevention of acute and delayed nausea and vomiting following both highly and moderately emetogenic chemotherapy. Helsinn Group Chief Executive Officer, Riccardo Braglia, said, "we are delighted to extend our successful collaboration with CJ CheilJedang with this new agreement. We are certain that CJ CheilJedang will bring this promising product to the forefront of the Korean market and help to improve not only patients' health but also their quality of life in a still significantly underserved medical area."
Mr. Kang, Seok Hee, Head of Pharmaceutical Business, Senior Executive VP, CJ CheilJedang said, "Having licensed Netu-Palo FDC(1) from Helsinn, CJ CheilJedang is continually committed to working for quality of life of patients suffering from chemotherapy induced nausea and vomiting, on the other hand, the agreement will help CJ CheilJedang strengthen its presence in the area of cancer supportive care in Korea.
About Helsinn Group
Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States. Helsinn's business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. Helsinn is an important player in cancer supportive care. Helsinn Group in- licenses early-to-late stage new chemical entities, completes their development through the performance of pre-clinical /clinical studies and Chemistry, Manufacturing, and Control (CMC) development, and files and attains their market approvals worldwide. Helsinn's products are out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how whom Helsinn assists and supports by providing a full range of product and scientific management services, including commercial, regulatory financial, legal, and medical marketing advice. The active pharmaceutical ingredients and the finished products are manufactured according to the highest quality, safety, and environmental standards at Helsinn's GMP facilities in Switzerland and Ireland and supplied worldwide to its customers. Further information on Helsinn Group is available at: www.helsinn.com
About CJ CheilJedang
CJ CheilJedang belongs to the CJ group which is engaged in Food & Food services, Homeshopping & Logistics, Entertainment & Media, Bio & Pharmaceutical industries in South Korea. The vision of CJ CheilJedang is to be a Global Food & Bio Company with capable people, innovation and speed. For this, CJ CheilJedang sets up the mission that to raise and secure best talented people, to take new dynamic force for growth with bio/food technology, to lead the market of health/convenience with deep understanding of customers and to make young corporate culture whose spirit is challengeable and innovative. For further information, please visit us at: www.cj.co.kr
Source: Helsinn Group and CJ CheilJedang.
(1) NETU-PALO FDC: Netupitant - Palonosetron Fixed Dose Combination
Contact:
For Helsinn Group
Paola Bonvicini
Head of Communication & Press Office
Phone: +41/91/985'21'21
E-Mail: Info-hhc@helsinn.com
For CJ CheilJedang
Kwang Hee Hong
Head of Pharma Licensing
Phone: +82/2/6740-2181
E-Mail: khong@cj.net